We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology

News   Nov 19, 2010

 
Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology
 
 
Advertisement
 

RELATED ARTICLES

Expert Panel Makes Weak Recommendation for Use of Remdesivir To Treat Severe COVID-19

News

International experts have made a weak recommendation for the use of remdesivir in patients with severe COVID-19, advising continuation of patient enrolment for ongoing clinical trials of remdesivir to enable the collection of additional data.

READ MORE

Positive Results Reported for Phase 2 Study of Lyme Disease Vaccine Candidate

News

Positive initial results have been reported for the Phase 2 study of Lyme disease vaccine candidate VLA15.

READ MORE

Botox Injections May Reduce Depression

News

Researchers have mined the U.S. Food and Drug Administration’s Adverse Effect Reporting System (FAERS) database and have discovered that people who received Botox injections reported depression significantly less often than those undergoing alternative treatments for the same condition.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE